The development of neutralizing antibodies against SARS-CoV-2 and their common features.
J Mol Cell Biol
; 12(12): 980-986, 2020 11 25.
Article
in English
| MEDLINE | ID: covidwho-998366
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a great demand for effective therapies for the prevention and treatment of COVID-19. Developing therapeutic neutralizing antibodies (NAbs), which could block viral infection, is such a promising approach, as NAbs have been successfully applied to the treatment of other viral infections. The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs, and many of which are now actively tested in clinical trials. Here, we review the approaches applied for SARS-CoV-2 NAb development, and discuss the emerging technologies underlining the antibody discovery. We further summarize the common features of these antibodies including the shared neutralizing epitopes and sequence features.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antibodies, Neutralizing
/
SARS-CoV-2
/
COVID-19
/
Antibodies, Viral
Type of study:
Prognostic study
Limits:
Animals
/
Humans
Language:
English
Journal:
J Mol Cell Biol
Journal subject:
Molecular Biology
Year:
2020
Document Type:
Article
Affiliation country:
Jmcb
Similar
MEDLINE
...
LILACS
LIS